The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
- 주제(키워드) Polycythemia vera , Thrombocythemia , essential , Primary myelofibrosis , Practice guideline
- 주제(기타) Medicine, General & Internal
- 설명문(일반) [Kim, Sung-Yong] Konkuk Univ, Dept Internal Med, Div Hematol, Med Ctr, Seoul, South Korea; [Bae, Sung Hwa] Daegu Catholic Univ, Dept Internal Med, Sch Med, Daegu, South Korea; [Bang, Soo-Mee] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea; [Eom, Ki-Seong] Catholic Univ Korea, Coll Med, Dept Hematol, Seoul St Marys Hematol Hosp, Seoul, South Korea; [Hong, Junshik] Seoul Natl Univ Hosp, Dept Internal Med, Div Hematol & Med Oncol, Seoul, South Korea; [Jang, Seongsoo] Univ Ulsan, Asan Med Ctr, Dept Lab Med, Coll Med, Seoul, South Korea; [Jung, Chul Won] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; [Kim, Hee-Jin] Sungkyunkwan Univ, Samsung Med Ctr, Dept Lab Med & Genet, Sch Med, Seoul, South Korea; [Kim, Ho Young] Hallym Univ, Dept Internal Med, Med Ctr, Anyang, South Korea; [Kim, Min Kyoung] Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea; [Kim, Soo-Jeong] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Mun, Yeung-Chul] Ewha Womans Univ, Dept Internal Med, Sch Med, Seoul, South Korea; [Nam, Seung-Hyun] Vet Hlth Serv Med Ctr, Dept Internal Med, Seoul, South Korea; [Park, Jinny] Gachon Univ, Dept Internal Med, Div Hematol, Gil Med Ctr, Incheon, South Korea; [Won, Jong-Ho] Soonchunhyang Univ, Dept Internal Med, Div Hematol Oncol, Coll Med, Seoul, South Korea; [Choi, Chul Won] Korea Univ, Dept Internal Med, Div Hematol Oncol, Guro Hosp, Seoul, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- OA유형 Green Published, gold
- 발행기관 KOREAN ASSOC INTERNAL MEDICINE
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000175417
- 본문언어 영어
- Published As http://dx.doi.org/10.3904/kjim.2020.319
- PubMed https://pubmed.ncbi.nlm.nih.gov/33147902
초록/요약
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional somatic mutations have a clinical impact on the prognosis of patients harboring these genetic abnormalities. Treatment strategies have also advanced with the introduction of JAK inhibitors, one of which has been approved for the treatment of patients with myelofibrosis and those with hydroxyurea-resistant or intolerant polycythemia vera. Recently developed drugs aim to elicit hematologic responses, as well as symptomatic and molecular responses, and the response criteria were refined accordingly. Based on these changes, we have revised the guidelines and present the diagnosis, treatment, and risk stratification of MPNs encountered in Korea.
more